Search
Derazantinib
go.drugbank.com/drugs/DB14889InvestigationalDerazantinib is under investigation in clinical trial NCT03230318 (Derazantinib in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma).
VS-4718
go.drugbank.com/drugs/DB15273InvestigationalVS-4718 is under investigation in clinical trial NCT02215629 (Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia).
Telatinib
go.drugbank.com/drugs/DB15393InvestigationalTelatinib is under investigation in clinical trial NCT03817411 (Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer).
Camidanlumab tesirine
go.drugbank.com/drugs/DB16411InvestigationalCamidanlumab tesirine is under investigation in clinical trial NCT04639024 (ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN).
Danburstotug
go.drugbank.com/drugs/DB19064InvestigationalDanburstotug is under investigation in clinical trial NCT04809012 (Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors).
Nelotanserin
go.drugbank.com/drugs/DB12555InvestigationalIt increases non-REM sleep, the most restorative phase of the sleep cycle, without sacrificing REM or dream sleep.
Quisinostat
go.drugbank.com/drugs/DB12985InvestigationalQuisinostat has been used in trials studying the treatment of Lymphoma, Neoplasms, Myelodysplastic Syndromes, and Advanced or Refractory Leukemia.
Vactosertib
go.drugbank.com/drugs/DB15310InvestigationalVactosertib is under investigation in clinical trial NCT03724851 (Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer).
AZD-8330
go.drugbank.com/drugs/DB06061InvestigationalAZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. AZD-8330 has shown tumor suppressive activity in multiple preclinical models of h...
Zosuquidar
go.drugbank.com/drugs/DB06191InvestigationalZosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with t...